Search Results - "Badovinac Crnjevic, Tanja"

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study by Kirschbrown, Whitney P., Wynne, Chris, Kågedal, Matts, Wada, Russ, Li, Hanbin, Wang, Bei, Nijem, Ihsan, Badovinac Crnjevic, Tanja, Gasser, Helena, Heeson, Sarah, Eng‐Wong, Jennifer, Garg, Amit

“…Adding pertuzumab to trastuzumab (both monoclonal antibodies targeting human epidermal growth factor receptor 2 [HER2]) has proven survival benefits when…”
Get full text

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study by Tan, Antoinette R, Im, Seock-Ah, Mattar, André, Colomer, Ramon, Stroyakovskii, Daniil, Nowecki, Zbigniew, De Laurentiis, Michelino, Pierga, Jean-Yves, Jung, Kyung Hae, Schem, Christian, Hogea, Alexandra, Badovinac Crnjevic, Tanja, Heeson, Sarah, Shivhare, Mahesh, Kirschbrown, Whitney P, Restuccia, Eleonora, Jackisch, Christian

“…A subcutaneous formulation of pertuzumab and trastuzumab with recombinant human hyaluronidase in one ready-to-use, fixed-dose combination vial (pertuzumab,…”
Get full text

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial by Krop, Ian E, Dr, Kim, Sung-Bae, Prof, Martin, Antonio Gonzalez, MD, LoRusso, Patricia M, Prof, Ferrero, Jean-Marc, MD, Badovinac-Crnjevic, Tanja, MD, Hoersch, Silke, MSc, Smitt, Melanie, MD, Wildiers, Hans, Prof

“…Summary Background In the randomised, parallel assignment, open-label, phase 3 TH3RESA study, progression-free survival was significantly longer with…”
Get full text

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy by Urruticoechea, Ander, Rizwanullah, Mohammed, Im, Seock-Ah, Ruiz, Antonio Carlos Sánchez, Láng, István, Tomasello, Gianluca, Douthwaite, Hannah, Badovinac Crnjevic, Tanja, Heeson, Sarah, Eng-Wong, Jennifer, Muñoz, Montserrat

“…Purpose To assess the efficacy and safety of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor…”
Get full text

Challenges to effective cancer control in China, India, and Russia by Goss, Paul E, Prof, Strasser-Weippl, Kathrin, MD, Lee-Bychkovsky, Brittany L, MD, Fan, Lei, MD, Li, Junjie, MD, Chavarri-Guerra, Yanin, MD, Liedke, Pedro E R, MD, Pramesh, C S, Prof, Badovinac-Crnjevic, Tanja, MD, Sheikine, Yuri, MD, Chen, Zhu, Prof, Qiao, You-lin, Prof, Shao, Zhiming, MD, Wu, Yi-Long, Prof, Fan, Daiming, Prof, Chow, Louis W C, Prof, Wang, Jun, PhD, Zhang, Qiong, PhD, Yu, Shiying, Prof, Shen, Gordon, SM, He, Jie, MD, Purushotham, Arnie, Prof, Sullivan, Richard, Prof, Badwe, Rajendra, MS, Banavali, Shripad D, Prof, Nair, Reena, MD, Kumar, Lalit, Prof, Parikh, Purvish, Prof, Subramanian, Somasundarum, Prof, Chaturvedi, Pankaj, Prof, Iyer, Subramania, Prof, Shastri, Surendra Srinivas, Prof, Digumarti, Raghunadhrao, Prof, Soto-Perez-de-Celis, Enrique, MD, Adilbay, Dauren, PhD, Semiglazov, Vladimir, Prof, Orlov, Sergey, Prof, Kaidarova, Dilyara, Prof, Tsimafeyeu, Ilya, MD, Tatishchev, Sergei, MD, Danishevskiy, Kirill D, Prof, Hurlbert, Marc, PhD, Vail, Caroline, BS, St Louis, Jessica, BA, Chan, Arlene, Prof

“…Summary Cancer is one of the major non-communicable diseases posing a threat to world health. Unfortunately, improvements in socioeconomic conditions are…”
Get full text

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study by Hurvitz, Sara A, Bardia, Aditya, Quiroga, Vanesa, Park, Yeon Hee, Blancas, Isabel, Alonso-Romero, José Luis, Vasiliev, Aleksandr, Adamchuk, Hryhoriy, Salgado, Marcelo, Yardley, Denise A, Berzoy, Oleksandr, Zamora-Auñón, Pilar, Chan, David, Spera, Gonzalo, Xue, Cloris, Ferreira, Erika, Badovinac Crnjevic, Tanja, Pérez-Moreno, Pablo Diego, López-Valverde, Vanesa, Steinseifer, Jutta, Fernando, Tharu M, Moore, Heather M, Fasching, Peter A

“…The development of more potent selective oestrogen receptor antagonists and degraders (SERDs) that can be orally administered could help to address the…”
Get full text

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics by Liu, Stephanie N., Lu, Tong, Jin, Jin Y., Li, Chunze, Girish, Sandhya, Melnikov, Fjodor, Badovinac Crnjevic, Tanja, Machackova, Zuzana, Restuccia, Eleonora, Kirschbrown, Whitney P.

“…PERJETA (pertuzumab), administered with Herceptin (trastuzumab), is used in the treatment of human epidermal growth factor receptor 2‐positive breast cancer…”
Get full text

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study by Wang, Bei, Deng, Rong, Hennig, Stefanie, Badovinac Crnjevic, Tanja, Kaewphluk, Monika, Kågedal, Matts, Quartino, Angelica L., Girish, Sandhya, Li, Chunze, Kirschbrown, Whitney P.

“…Purpose To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous…”
Get full text

Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study by Wang, Bei, Deng, Rong, Hennig, Stefanie, Badovinac Crnjevic, Tanja, Kaewphluk, Monika, Kågedal, Matts, Quartino, Angelica L., Girish, Sandhya, Li, Chunze, Kirschbrown, Whitney P.

Get full text

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial by Goss, Paul E, Prof, Hershman, Dawn L, Prof, Cheung, Angela M, Prof, Ingle, James N, Prof, Khosla, Sundeep, MD, Stearns, Vered, Prof, Chalchal, Haji, MD, Rowland, Kendrith, Prof, Muss, Hyman B, Prof, Linden, Hannah M, Prof, Scher, Judite, MSc, Pritchard, Kathleen I, Prof, Elliott, Catherine R, MSc, Badovinac-Crnjevic, Tanja, MD, St Louis, Jessica, BA, Chapman, Judith-Anne W, Prof, Shepherd, Lois E, Prof

“…Summary Background Treatment of breast cancer with aromatase inhibitors is associated with damage to bones. NCIC CTG MA.27 was an open-label, phase 3,…”
Get full text

High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer by Tanja, Badovinac Črnjević, Giulio, Spagnoli, Antonio, Juretić, Jasminka, Jakić-Razumović, Paula, Podolski, Nera, Šarić

“…Recent studies indicate that ER/PR/HER-2-negative (triple-negative, TN) breast cancers may be “CTA-rich” tumors, suggesting the possibility of CTA-based cancer…”
Get full text

Describing U.S. real-world patients (pts) with hormone receptor-positive early breast cancer (HR+ EBC) by risk status by Downer, Mary K., Yakubu, Amin, Pérez-Moreno, Pablo Diego, Steenrod, Anna, Badovinac Crnjevic, Tanja, Machackova, Zuzana

“…e12548 Background: Despite high endocrine therapy (ET) efficacy in HR+ EBC, there is an unmet need to improve outcomes across risk statuses. We describe HR+…”
Get full text

Neoadjuvant giredestrant + palbociclib (P) vs. anastrozole (A) + P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2– eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study by Park, Yeon Hee, Quiroga, Vanesa, Fasching, Peter A., Bardia, Aditya, López-Valverde, Vanesa, Badovinac Crnjevic, Tanja, Steinseifer, Jutta, Devine, Jacob, Hurvitz, Sara A.

“…591 Background: Endocrine therapies (ETs) are the therapeutic mainstay for ER+ BC but persistent adverse events (AEs; eg joint pain, especially with aromatase…”
Get full text

lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC) by Geyer, Charles, Bardia, Aditya, Harbeck, Nadia, Rimawi, Mothaffar F., Hurvitz, Sara A., Martin, Miguel, Loi, Sherene, Saji, Shigehira, Jung, Kyung Hae, Werutsky, Gustavo, Stroyakovskiy, Daniil, López-Valverde, Vanesa, Davis, Michael, Badovinac Crnjevic, Tanja, Pérez-Moreno, Pablo Diego, Schmid, Peter

“…TPS616 Background: Despite best management with standard ETs, ≤ 20% of pts with ER+, HER2– eBC develop resistance (due to ESR1 mutations that can drive…”
Get full text

Abstract PS7-23: Neoadjuvant and adjuvant therapy (NAT/AT) treatment patterns and clinical characteristics in a real-world cohort of US patients with HR+/HER2− early breast cancer (eBC) by Downer, Mary K, Craggs, Christopher, Dhillon, Preet, Luhn, Patricia, Flores-Avile, Carlos, Tan, Amie, Patre, Monika, Schimmoller, Frauke, Crnjevic, Tanja Badovinac

“…Abstract Background: Treatment patterns in hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)− eBC continue to evolve. While AT remains the…”
Get full text

Abstract OT-09-06: Phase II neoadjuvant study of GDC-9545 + palbociclib (palbo) vs anastrozole (A) + palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC) by Hurvitz, Sara A, Fasching, Peter A, Park, Yeon Hee, Quiroga, Vanesa, Crnjevic, Tanja Badovinac, Fresco, Rodrigo, López-Valverde, Vanesa, Steinseifer, Jutta, Ye, Chenglin, Bardia, Aditya

“…Abstract Background Endocrine therapies (ETs) are the mainstay of ER+ BC management; however, many patients (pts) have disease relapse or develop therapeutic…”
Get full text

Changes in patient (pt), tumor, and treatment characteristics over time in 1 st line (1L) trastuzumab (H) plus taxane (T; paclitaxel/docetaxel) arms in HER2-positive metastatic breast cancer (MBC) trials by Badovinac Crnjevic, Tanja, Restuccia, Eleonora, Michielin, Francesca, Eng-Wong, Jennifer, Nüesch, Eveline

“…Abstract only…”
Get full text

Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study by Fasching, Peter A., Bardia, Aditya, Quiroga, Vanesa, Park, Yeon Hee, Blancas, Isabel, Alonso, Jose Luis, Vasilyev, Alexander, Adamchuk, Hryhoriy, Salgado, Marcelo Ramos Tejo, Yardley, Denise A., Spera, Gonzalo, Xue, Cloris, Ferreira, Erika, Badovinac Crnjevic, Tanja, Pérez-Moreno, Pablo Diego, López-Valverde, Vanesa, Steinseifer, Jutta, Fernando, Tharu M., Moore, Heather M., Hurvitz, Sara A.

“…589 Background: Endocrine therapy (ET) is the therapeutic mainstay for ER+ BC. Giredestrant is a highly potent, nonsteroidal, oral, selective ER antagonist and…”
Get full text

Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC) by Bardia, Aditya, Schmid, Peter, Harbeck, Nadia, Rimawi, Mothaffar F, Hurvitz, Sara A, Loi, Sherene, Saji, Shigehira, Jung, Kyung Hae, Werutsky, Gustavo, Stroyakovskii, Daniil, López-Valverde, Vanesa, Tesarowski, David, Ye, Chenglin, Davis, Michael, Crnjevic, Tanja Badovinac, Perez-Moreno, Pablo Diego, Geyer, Charles E

“…Abstract BACKGROUND ETs that target ER activity and/or estrogen synthesis are the mainstay of ER+ BC treatment. Despite best management, up to 20% of pts with…”
Get full text

Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study by Tan, Antoinette R, Im, Seock-Ah, Mattar, Andre, Colomer, Ramon, Stroyakovskii, Daniil, Nowecki, Zbigniew, De Laurentiis, Michelino, Pierga, Jean-Yves, Jung, Kyung Hae, Schem, Christian, Heeson, Sarah, Shivhare, Mahesh, Kirschbrown, Whitney P., Restuccia, Eleonora, Crnjevic, Tanja Badovinac, Jackisch, Christian

“…Abstract Background: Intravenous pertuzumab (P IV) + trastuzumab (H IV) + chemotherapy (CT) improves outcomes in patients (pts) with HER2-positive breast…”
Get full text